Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients
Open Access
- 1 January 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Critical Care Medicine
- Vol. 4 (3) , 230-239
Abstract
Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patientsKeywords
This publication has 31 references indexed in Scilit:
- JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneBlood, 2012
- Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdensExperimental Hematology, 2008
- Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burdenLeukemia, 2007
- Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemiaBlood, 2006
- Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSGLeukemia & Lymphoma, 2000
- Erythromelalgia and Vascular Complications in Polycythemia VeraSeminars in Thrombosis and Hemostasis, 1997
- Erythromelalgic, Thrombotic and Hemorrhagic Manifestations in 50 Cases of ThrombocythemiaLeukemia & Lymphoma, 1996
- Hydroxyurea in Essential ThrombocytosisNew England Journal of Medicine, 1995
- Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: Relationship with platelet countAnnals of Hematology, 1994
- VASCULAR OCCLUSIVE EPISODES AND VENOUS HÆMATOCRIT IN PRIMARY PROLIFERATIVE POLYCYTHÆMLXThe Lancet, 1978